Benzinga

Benzinga

Benzinga

martes, agosto 25

Alnylam Pharmaceuticals Inc

ALNYNASDAQ
Trade with Public
Trade with Public
$236.01
-0.21-0.09%
al cierre: Aug 21, 5:00 PM EST
$236.50
0.280.12%
Premercado: 6:41 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Alnylam Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alnylam Pharmaceuticals (ALNY).

Price Target Range — 7 Quarters

Analyst Consensus — 22 Analysts

1S.Buy
19Buy
2Hold
Consensus RatingBuy# Analysts22Avg. Consensus PT$421Upside to Avg. PT+77.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$318
Aug 14, 2026Wells FargoDerek ArchilaPT CutEqual-Weight$316→$256
More with Benzinga EdgeGet Access

Analyst Ratings News

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Avi Kapoor

PRO
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform rating and announces Price Target of $318.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $316 to $256.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $315

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $410 to $315.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $455

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $485 to $455.
Benzinga Newsdesk

PRO
Raymond James Upgrades Alnylam Pharmaceuticals to Strong Buy, Maintains Price Target to $420

Raymond James analyst Martin Auster upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Outperform to Strong Buy and maintains the price target from $420 to $420.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved